ACHLライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (18 5月 2024 @ 05:00):

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors...

Stats
本日の出来高	115 040
平均出来高	582 007
時価総額	38.94M
EPS	$0 ( 2024-05-08 )
次の収益日	( $-0.410 ) 2024-08-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.590
ATR14	$0.0200 (2.11%)

Achilles Therapeutics plc 相関

10 最も正の相関
CRSP	0.844
SGMO	0.843
GRPN	0.833
NUVL	0.821
ANGI	0.818
FONR	0.806

10 最も負の相関
RGLD	-0.876

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Achilles Therapeutics plc 相関 - 通貨/商品

0.10
( neutral )

0.01
( neutral )

0.00
( neutral )

-0.38
( neutral )

Achilles Therapeutics plc 財務諸表

Annual	2023
収益:	$0
総利益:	$-4.73M (0.00 %)
EPS:	$-1.750

FY	2023
収益:	$0
総利益:	$-4.73M (0.00 %)
EPS:	$-1.750

FY	2022
収益:	$0
総利益:	$-3.69M (0.00 %)
EPS:	$-1.820

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.36

Financial Reports:

No articles found.

Achilles Therapeutics plc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Achilles Therapeutics plc

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.